The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Provenge News

erisian
erisian CSN Member Posts: 107
edited March 2014 in Prostate Cancer #1
http://www.zerocancer.org/site/News2?page=NewsArticle&id=11424

Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented

"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."

Let's hope so.
Like Care

Comments

  • erisian
    erisian CSN Member Posts: 107
    #2
    More info
    "...PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death..."

    Here are a couple of links on the subject:

    Dendreon press release:
    http://tinyurl.com/Provenge-PR

    PDF of presentation on the IMPACT study given at ASCO-GU conference:
    http://tinyurl.com/Provenge-pdf
    Like Care

Discussion Boards